Norges forskningsråd
The Research Council of Norway

FUGE
Functional genomics

2002 to 2009: 1.6 billion kroner to a total of 233 projects.

Established a series of national technology platforms based on vital biotechnological research tools and methods – such as proteomics, genomics, bioimaging, structural analysis and bioinformatics

Norge henger med på forskningsfronten: internasjonal sammenligning av utviklingen innen biotekforskningspublikasjoner (indeksår = 1990)



Kilde: DAMVAD, Sluttevaluering av FUGE, 2010. Basert på data fra Web of Science. N = 4,259.

Norge henger med på forskningsfronten: internasjonal sammenligning av utviklingen innen biotekforskningspublikasjoner (indeksår = 1990)



"…været en national succes: Det har løftet norsk forskning, det har skabt erhvervsmæssig værdi, og det har understøttet en samfundsmæssig robust innovation. Evalueringen understreger, at det har betydning for forskningsmiljøerne og erhvervslivet i Norge, at man i FUGE har opstillet klare forskningspolitiske visioner og tænkt langsigtet – med en programperiode på knap ti år er der selv i international sammenhæng tale om et meget langsigtet perspektiv for et forskningsprogram. De principper bør fortsat være grundlæggende i de norske strategiske satsninger."


5-year relative survival by period and type
Acute leukemia, females
Lymphatic
Myeloid
All types
100
80
60
40
20
0
%
?
1957-61
1962-66
1967-71
1972-76
1977-81
1982-86
1987-91
1992-96
Period of diagnosis
Akutt myelogen leukemi, ca 120/år, flest over 65 år, median 3 års overlevelse <20%.
Copyright American Society of Hematology

Potentiated signaling in cancer cells with
mutations in intracellular signaling enzyme
Irish, Hovland et al. Cell 2004


p53 protein biosignature and survival
Full length
β/γ
0.4
0.3
0.2
0.1
0.0
-0.1
-0.2
-0.3
-0.4
Correlation
Anensen, Hjelle et al. Oncogene 2011




Control, day 21
Treated
Emmet McCormack, UiB

BERGEN BIO AS
About Us
Technology Platform
Pipeline
Partnering & Collaborations
News & Events
Navigating the right path
to better cancer targets.


KinN Therapeutics AS
In vitro
Molecular
Future medical care will focus around customised therapy and customised imaging for the optimal management of the individual patient...
In vivo
Clinical
Preclinical modelling and imaging

® Sunniva Seim